These included a subgroup of M-CLL with neutral HCDR3 who displayed intermediate clinical, genetic, and prognostic features between the classical U-CLL and M-CLL patients with a negatively charged BCR. The gene discussed is BCR; the disease is B-cell chronic lymphocytic leukemia.